Omar A. Egenov

Omar A. Egenov

Auto-generated profile, based on publicly available information

Omar A. Egenov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
APA.N. Polyakov
A.N. Polyakov
YPYu.I. Patyutko
Yu.I. Patyutko
NKN.E. Kudashkin
N.E. Kudashkin
DKD.M. Kantieva
D.M. Kantieva
KRK.A. Romanova
K.A. Romanova
DPD.V. Podluzhnyi
D.V. Podluzhnyi
ЦЕЛЬ ИССЛЕДОВАНИЯ Определить целесообразность необратимой электропорации (НЭП) при местно-распространенной аденокарциноме поджелудочной железы на основе собственного опыта и данных литературы. МАТЕРИАЛ И МЕТОДЫ С 2015 по 2022 г. 23 пациентам выполнена НЭП по поводу местно-распространенного рака поджелудочной железы после индукционной химиотерапии. НЭП чаще проводили во время лапаротомии (n=22). В 1 случае ее сочетали с паллиативной панкретодуоденальной резекцией. После процедуры адъювантную химиотерапию получили 19 (86,3%) пациентов. Контрольное обследование включало КТ/МРТ брюшной полости с внутривенным контрастированием, рентгенографию или КТ органов грудной клетки, определение опухолевого маркера CA 19-9 через 1 мес после операции, затем каждые 3 мес. РЕЗУЛЬТАТЫ Осложнения после НЭП развились у 5 (21,7%) пациентов. У 3 (13,0%) больных отмечена аритмия, у 3 (8,7%) — панкреонекроз. Девяностодневная летальность после процедуры составила 4,3% (n=1), причина — панкреонекроз. По интраоперационным данным и результатам первого обследования (КТ/МРТ) весь опухолевый инфильтрат был обработан в 21 (91,3%) случае. Медиана времени наблюдения составила 19 мес. Медиана времени до местного рецидива составила 15 мес. Изолированный локальный рецидив наблюдался у 7 больных, 3 из них проведена лучевая терапия, 1 — повторная НЭП. Отдаленные метастазы обнаружены у 11 больных; системная терапия была возобновлена. Медиана времени до прогрессирования составила 7 мес после НЭП и 14 мес после начала индукционной химиотерапии. Медиана общей выживаемости составила 16 мес после электропорации и 25 мес после индукционной химиотерапии. ЗАКЛЮЧЕНИЕ Необратимая электропорация может быть применима у тщательно отобранных пациентов с местно-распространенной аденокарциномой поджелудочной железы после успешной индукционной химиотерапии. Метод обеспечивает локальный контроль, но влияние на отдаленные результаты и целесообразность рутинного использования следует определить в рандомизированных исследованиях.

15 December 2021 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
OEOmar A. Egenov
Omar A. Egenov
ISIvan S. Stilidi
Ivan S. Stilidi
АTАleksandra S. Tyulyandina
Аleksandra S. Tyulyandina
Aim. To analyze the data available in the modern literature on the role of repeated cytoreduction in the complex treatment of relapses ovarian cancer (OC). Materials and methods. Sources were searched in the following systems Clinicaltrials.gov, PubMed, Medline, NCCN, Scopus, Gynecol Oncol, Elibrary. After analyzing the literature review, 31 sources were used, published from January 1989 to December 2020. Results. The main method of treatment relapses of ОС is administration of systemic chemotherapy. The role of surgical treatment has been actively discussed for several decades. According to the available data of retrospective, prospective, randomized trials, performing surgery following chemotherapy had a favorable effect on the long-term results of treatment just in case of achieving complete cytoreduction in comparison with only chemotherapeutic treatment of platinum-sensitive recurrence of ОС. A validated prognostic model helps to perform the selection of suitable patients for surgical treatment, therefore, the correct selection for secondary cytoreduction allows to identify the patients with a high chance of achieving сomplete cytoreduction, which reduces the number of ineffective operations in patients with residual tumors. Conclusion. Complete cytoreduction of all macroscopically detectable recurrent tumor lesions in combination with subsequent systemic chemotherapy leads to an improvement in progression-free survival and life expectancy in a carefully selected group of patients with platinum-sensitive recurrent OC. Secondary cytoreduction in platinum-refractory and platinum-resistant relapses deteriorates the prognosis and doesn't lead to an increase in survival rates. Patient selection is the key point in secondary cytoreductive surgery. The choice of the methodology of selection of patients is in the process of discussion. When planning treatment, all patients with recurrent OC should be discussed at multidisciplinary teams with the participation of specialists in related specialties. Considering a surgical treatment option should be performed it in large centers with extensive experience in the surgical treatment of OC, relapses, performing complex multi-organ resections.

1 January 2019 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
ISI. S. Stilidi
I. S. Stilidi
SNS. N. Nered
S. N. Nered
MNM. P. Nikulin
M. P. Nikulin
OEO. A. Egenov
O. A. Egenov
APA. P. Petrosyan
A. P. Petrosyan
PAP. P. Arkhiri
P. P. Arkhiri
To assess severity, safety and functional advisability of distal pancreatectomy using original surgical technique developed in the Blokhin National Medical Research Centre of Oncology. There were 10 patients with duodenal malignancies who have undergone distal pancreatectomy in the Blokhin National Medical Research Centre of Oncology for the period 2006-2018. Distal pancreatectomy for primary duodenal tumors was performed in 8 patients, 2 patients underwent surgery for external invasion of the duodenum. Postoperative complications Clavien-Dindo grade 1 and 2 occurred in 4 (40%) patients. Surgical complication grade 2 occurred in 1 (10%) patient (pancreatic fistula with effective conservative management). There were no cases of leakage of duodenal stump and duodenojejunostomy, impaired bile flow and stenosis of anastomosis with delayed stomach emptying. Distal duodenectomyis associated with low postoperative morbidity, good functionality and quality of life. This procedure is preferred for non-epithelial and neuroendocrine tumors, as well as with secondary malignant duodenal invasion.

19 December 2025 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
APA.N. Polyakov
A.N. Polyakov
YPYu.I. Patyutko
Yu.I. Patyutko
AKAlexey Kotelnikov
Alexey Kotelnikov
IBI.S. Bazin
I.S. Bazin
ASA.YU. Syskova
A.YU. Syskova
DPD.V. Podluzhny
D.V. Podluzhny
Objective. To determine prognostic factors in resectable common bile duct (CBD) cancer and feasibility of adjuvant therapy. Material and methods. We retrospectively studied the results of pancreatoduodenectomy for CBD cancer in 1999—2023. Results. There were 89 patients, mortality rate was 5.6% (n=5), complications developed in 66 patients (74.2%), complications ≥ grade III — in 37 (41.7%) cases. Postoperative pancreatic fistula (POPF) grade B/C was detected in 29 (32.6%) cases. Postoperative chemotherapy was administered to 43 patients (gemcitabine-based therapy — 27, capecitabine alone — 15, capecitabine/oxaliplatin combination — 1). The median overall survival was 33 months, disease-free survival — 19 months. Among patients selected for assessment of long-term results (n=79), the median OS was 37 months, DFS — 30 months. Retroperitoneal invasion (RPI), pancreatic invasion (PI), perineural invasion (PNI), moderate/poor differentiation, R1 resection, retroperitoneal lymph node (LN) involvement worsened long-term results in multivariate analysis, regional LN involvement and elevated CA 19-9 — in univariate analysis. Accumulation of factors worsened prognosis. Postoperative chemotherapy improved OS (median OS 35 months vs. 16.5, p=0.035) in patients with two or more negative prognostic factors. Chemotherapy mode did not affect prognosis. Conclusion. Retroperitoneal, pancreatic and perineural invasion, R1 resection, moderate/poor tumor differentiation, lymph node involvement and elevated CA 19-9 are negative prognostic factors in CBD cancer. Postoperative capecitabine monotherapy is justified in patients with two or more negative factors.

12 April 2022 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
OEO. A. Egenov
O. A. Egenov
ATA. S. Tjulyandina
A. S. Tjulyandina
SNS. N. Nered
S. N. Nered
AKA. E. Kalinin
A. E. Kalinin
ASA. S. Shevchuk
A. S. Shevchuk
ISI. S. Stilidi
I. S. Stilidi
Objective: analysis of the immediate and long-term results of surgical treatment of patients with lymph node (Ln) involvement in recurrent ovarian cancer (OC), as well as the search for prognostic factors for progression-free survival (PfS) and overall survival (OS).Materials and methods. The retrospective analysis included patients under the age of 75 who underwent surgery for recurrence of OC with Ln involvement at n.n. Blokhin national medical Research Center of Oncology in the period from 2005 to 2020. All patients had previously received combined treatment due to a primary diagnosis of OC. Exclusion criteria: the presence of concomitant pathology in the decompensation phase, primary multiple malignant tumors and recurrences of non-epithelial ovarian tumors. The analysis of the main operational characteristics, the frequency of postoperative complications according to Clavien–Dindo within 30 days after surgery, PfS, OS, as well as parameters affecting the long-term results of treatment were performed.Results. The study included 123 patients: a cohort of isolated lesions of the Ln (n = 65) and a group of combined recurrence in the Ln and other anatomical locations (n = 58). The frequency of complete cytoreduction was significantly higher in the group of patients with isolated recurrence in the Ln: 86.62 % versus 53.4 % in patients with combined relapse, p 0.0001. The median duration of the operation was also significantly higher in patients with combined recurrence: 245 min versus 180 min in a cohort of patients with isolated recurrence in the Ln, p 0.0001. Postoperative complications of grade III B were more often observed in the group of combined recurrence: 6.8 % versus 1.5 % in the group of isolated recurrence in the Ln, p = 0.148. none of the patients in the group of isolated recurrence in the Ln had postoperative mortality, while in the group of combined recurrence 2 (3.4 %) patients died after surgery from developed complications. In patients with isolated recurrence in the Ln and combined recurrence of OC, the median PfS was significantly higher when complete cytoreduction was achieved: 31.0 months and 18.0 months versus 10.0 months and 9.0 months with incomplete repeated cytoreduction, p 0.0001. In patients with isolated recurrence in the Ln and combined recurrence of OC, the median OS was identically significantly higher when complete repeated cytoreduction was achieved: 97.0 months and 60.0 months versus 34.0 months and 27.0 months with incomplete cytoreduction, p 0.0001.Conclusion. Surgical treatment of recurrence of OC is justified only if it is possible to achieve complete cytoreduction and platinum-sensitive type of recurrence of OC. Low grade tumor, platinum-sensitive type of recurrence, absence of marker recurrence of OC, isolated recurrence in Ln, complete repeated cytoreduction and lymphodissection were identified as predictors of PfS in multivariate analysis. The following factors had an independent favorable effect on OS in multivariate analysis: low tumor grade, platinum-sensitive type of recurrence, satisfactory overall status on the ECOg scale (0–1 points) at the time of detection of relapse, isolated recurrence in the Ln and complete repeated cytoreduction.

22 October 2025 in Russian Journal of Anesthesiology and Reanimatology
Verified
Journal Article
Closed access
OVO.S. Vlasenko
O.S. Vlasenko
APA.N. Polyakov
A.N. Polyakov
SMS.O. Matveeva
S.O. Matveeva
NKN.E. Kudashkin
N.E. Kudashkin
OEO.A. Egenov
O.A. Egenov
ASA.V. Sytov
A.V. Sytov
Objective. To evaluate the effect of first-day infusion and pancreatic acinar structures on the incidence of postoperative pancreatic fistulas (POPF) and complications after pancreatoduodenectomy. Material and methods. A retrospective study included patients who underwent pancreatoduodenectomy in 2024. Results. There were 79 patients: group 1 (n=38) — infusion ≥4.5 ml/kg/h on day 1, group 2 (n=41) — infusion <4.5 ml/kg/h. The median of acinar structures was 65%. POPF were found in 23.6% (n=9) and 53.6% (n= 22) of patients, respectively (p=0.021). POPF type B prevailed (21.0% (n=8) and 51.2% (n=21) of patients, respectively, p=0.033). Clavien-Dindo grade III—V complications occurred in 26.3% (n=10) and 58.5% (n=24) of patients, respectively (p=0.022). Multifactorial analysis showed that daily infusion <4.5 ml/kg/h (OR=3.938; 95% CI 1.461—10.614; p=0.025) and acinar structures ≥65% (OR=12.889; 95% CI 4.285—38.772; p=0.001) were predictors of type B POPF. Acinar structures ≥65% were predictors of Clavien-Dindo grade ≥III complications (OR=11.487; 95% CI 3.853—34.243; p=0.003). Conclusion. Daily infusion <4.5 ml/kg/h (p=0.025) and acinar structures ≥65% (p=0.001) increase the incidence of type B POPF after pancreatoduodenectomy. Acinar structures ≥65% increase the incidence of Clavien-Dindo ≥ grade III complications (p=0.003).